Drug Profile
PKX 001
Alternative Names: AAGP; PKX-001Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Institut National des Sciences Appliquees de Rouen; ProtoKinetix
- Developer ProtoKinetix; University of Alberta
- Class Antihyperglycaemics; Cardiovascular therapies; Eye disorder therapies; Glycopeptides; Glycoproteins; Small molecules
- Mechanism of Action Antioxidants; Free radical scavengers; Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Type 1 diabetes mellitus
- Preclinical Age-related macular degeneration; Cardiovascular disorders; Dry eyes
Most Recent Events
- 20 Jul 2022 University of Alberta completes enrolment in its phase I trial for type-1 diabetes mellitus in Canada (NCT03073577)
- 24 May 2022 Phase-I development in Type-1 diabetes mellitus is ongoing in Canada (NCT03073577)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Canada